A predictive test that identifies patients at higher than average risk to develop wet AMD has the potential to improve clinical management by transforming surveillance protocols and improve therapeutic decision-making. A patient's knowledge about being at higher risk also makes it easier to take certain preventative steps such as no longer smoking, and switching to a healthier diet rich in vitamins, antioxidants, certain carotenoids, and omega-3 fatty acids. Smoking and diet are reported to be among the most important modifiable risk factors associated with AMD.
Incidence of AMD
AMD is the most common cause of visual impairment and the leading cause of blindness in the elderly population in the developed world, the prevalence of which increases with advancing age. It is estimated that there are currently 9.1 million patients in the USA with AMD, 1.7 million suffering with the vision-threatening late stage complications of choroidal neovascularization (CNV) or geographic atrophy. Moreover, it is predicted that the number of cases of early AMD will increase to 17.8 million by 2050 and if untreated, cases of late-stage blinding AMD will increase to 3.8 million.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved